{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T22:49:27Z","timestamp":1784328567209,"version":"3.55.0"},"reference-count":74,"publisher":"Japan Atherosclerosis Society","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Atheroscler Thromb","JAT"],"published-print":{"date-parts":[[2017]]},"DOI":"10.5551\/jat.rv16009","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T17:11:12Z","timestamp":1487869872000},"page":"360-372","source":"Crossref","is-referenced-by-count":10,"title":["Lipid Lowering Therapy to Modify Plaque Microstructures:"],"prefix":"10.5551","volume":"24","author":[{"given":"Yu","family":"Kataoka","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, National Cerebral & Cardiovascular Centre"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Andrews","sequence":"additional","affiliation":[{"name":"Heart Health, South Australian Health & Medical Research Institute, University of Adelaide"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Puri","sequence":"additional","affiliation":[{"name":"Quebec Heart & Lung Institute, Laval University, Quebec City"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Psaltis","sequence":"additional","affiliation":[{"name":"Heart Health, South Australian Health & Medical Research Institute, University of Adelaide"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Heart Health, South Australian Health & Medical Research Institute, University of Adelaide"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Ballantyne C, Arroll B, Shepherd J: Lipids and CVD management: towards a global consensus. Eur Heart J, 2005; 26: 2224-2231","DOI":"10.1093\/eurheartj\/ehi373"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994; 344: 1383-1389","DOI":"10.1016\/S0140-6736(94)90566-5"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004; 35: 1495-1504","DOI":"10.1056\/NEJMoa040583"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Austin PC, Mamdani MM: Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22\/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada. Circulation, 2005; 112: 1296-1300","DOI":"10.1161\/CIRCULATIONAHA.104.531582"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH; CARDS investigators: Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet, 2004; 364: 685-696","DOI":"10.1016\/S0140-6736(04)16895-5"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N Engl J Med, 1998; 339: 1349-1357","DOI":"10.1056\/NEJM199811053391902"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG; PROSPER study group: PROspective Study of Pravastatin in the Elderly at Risk: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet, 2002; 360: 1623-1630","DOI":"10.1016\/S0140-6736(02)11600-X"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, Crowe T, Howard G, Cooper CJ, Brodie B, Grines CL, DeMaria AN; REVERSAL Investigators: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA, 2004; 291: 1071-1080","DOI":"10.1001\/jama.291.9.1071"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; ASTEROID Investigators: Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA, 2006; 295: 1556-1565","DOI":"10.1001\/jama.295.13.jpc60002"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE: Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med, 2011; 365: 2078-2087","DOI":"10.1056\/NEJMoa1110874"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11) Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE: Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA, 2016 Nov 15. doi: 10.1001\/jama.2016.16951. [Epub ahead of print]","DOI":"10.1001\/jama.2016.16951"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW; American College of Cardiology\/American Heart Association Task Force on Practice Guidelines: 2013 ACC\/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2013: S0735-S0797","DOI":"10.1161\/01.cir.0000437738.63853.7a"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) European Association for Cardiovascular Prevention &amp; Rehabilitation1, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D; ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees: ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J, 2011; 32: 1769-1818","DOI":"10.1093\/eurheartj\/ehr158"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Tearney GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezerra HG, Bouma B, Bruining N, Cho JM, Chowdhary S, Costa MA, de Silva R, Dijkstra J, Di Mario C, Dudek D, Falk E, Feldman MD, Fitzgerald P, GarciaGarcia HM, Gonzalo N, Granada JF, Guagliumi G, Holm NR, Honda Y, Ikeno F, Kawasaki M, Kochman J, Koltowski L, Kubo T, Kume T, Kyono H, Lam CC, Lamouche G, Lee DP, Leon MB, Maehara A, Manfrini O, Mintz GS, Mizuno K, Morel MA, Nadkarni S, Okura H, Otake H, Pietrasik A, Prati F, R\u00e4ber L, Radu MD, Rieber J, Riga M, Rollins A, Rosenberg M, Sirbu V, Serruys PW, Shimada K, Shinke T, Shite J, Siegel E, Sonoda S, Suter M, Takarada S, Tanaka A, Terashima M, Thim T, Uemura S, Ughi GJ, van Beusekom HM, van der Steen AF, van Es GA, van Soest G, Virmani R, Waxman S, Weissman NJ, Weisz G; International Working Group for Intravascular Optical Coherence Tomography (IWG-IVOCT): Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol, 2012; 59: 1058-1072","DOI":"10.1016\/j.jacc.2011.09.079"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Lowe HC, Narula J, Fujimoto JG, Jang IK: Intracoronary optical diagnostics current status, limitations, and potential. JACC Cardiovasc Interv, 2011; 4: 1257-1270","DOI":"10.1016\/j.jcin.2011.08.015"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM: Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol, 2000; 20: 1262-1275","DOI":"10.1161\/01.ATV.20.5.1262"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R: Update on acute coronary syndromes: the pathologists&apos; view. Eur Heart J, 2013; 34: 719-728","DOI":"10.1093\/eurheartj\/ehs411"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, Wrenn SP, Narula J: Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol, 2005; 25: 2054-2061","DOI":"10.1161\/01.ATV.0000178991.71605.18"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Libby P: Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol, 2012; 32: 2045-2051","DOI":"10.1161\/ATVBAHA.108.179705"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Bennett MR, Sinha S, Owens GK: Vascular Smooth Muscle Cells in Atherosclerosis. Circ Res, 2016; 118: 692-702","DOI":"10.1161\/CIRCRESAHA.115.306361"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Bentzon JF, Otsuka F, Virmani R, Falk E: Mechanisms of plaque formation and rupture. Circ Res, 2014; 114: 1852-1866","DOI":"10.1161\/CIRCRESAHA.114.302721"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Silvestre-Roig C, de Winther MP, Weber C, Daemen MJ, Lutgens E, Soehnlein O: Atherosclerotic plaque destabilization: mechanisms, models, and therapeutic strategies. Circ Res, 2014; 114: 214-226","DOI":"10.1161\/CIRCRESAHA.114.302355"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Yabushita H, Bouma BE, Houser SL, Aretz HT, Jang IK, Schlendorf KH, Kauffman CR, Shishkov M, Kang DH, Halpern EF, Tearney GJ: Characterization of human atherosclerosis by optical coherence tomography. Circulation, 2002; 106: 1640-1645","DOI":"10.1161\/01.CIR.0000029927.92825.F6"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Kubo T, Imanishi T, Takarada S, Kuroi A, Ueno S, Yamano T, Tanimoto T, Matsuo Y, Masho T, Kitabata H, Tsuda K, Tomobuchi Y, Akasaka T: Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J Am Coll Cardiol, 2007; 50: 933-939","DOI":"10.1016\/j.jacc.2007.04.082"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Kitabata H, Tanaka A, Kubo T, Takarada S, Kashiwagi M, Tsujioka H, Ikejima H, Kuroi A, Kataiwa H, Ishibashi K, Komukai K, Tanimoto T, Ino Y, Hirata K, Nakamura N, Mizukoshi M, Imanishi T, Akasaka T: Relation of micro-channel structure identified by optical coherence tomography to plaque vulnerability in patients with coronary artery disease. Am J Cardiol, 2010; 105: 1673-1678","DOI":"10.1016\/j.amjcard.2010.01.346"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Jia H, Abtahian F, Aguirre AD, Lee S, Chia S, Lowe H, Kato K, Yonetsu T, Vergallo R, Hu S, Tian J, Lee H, Park SJ, Jang YS, Raffel OC, Mizuno K, Uemura S, Itoh T, Kakuta T, Choi SY, Dauerman HL, Prasad A, Toma C, McNulty I, Zhang S, Yu B, Fuster V, Narula J, Virmani R, Jang IK: In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography. J Am Coll Cardiol, 2013; 62: 1748-1758","DOI":"10.1016\/j.jacc.2013.05.071"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Higuma T, Soeda T, Abe N, Yamada M, Yokoyama H, Shibutani S, Vergallo R, Minami Y, Ong DS, Lee H, Okumura K, Jang IK: A Combined Optical Coherence Tomography and Intravascular Ultrasound Study on Plaque Rupture, Plaque Erosion, and Calcified Nodule in Patients With ST-Segment Elevation Myocardial Infarction: Incidence, Morphologic Characteristics, and Outcomes After Percutaneous Coronary Intervention. JACC Cardiovasc Interv, 2015; 8: 1166-1176","DOI":"10.1016\/j.jcin.2015.02.026"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Kataoka Y, Puri R, Hammadah M, Duggal B, Uno K, Kapadia SR, Tuzcu EM, Nissen SE, King P, Nicholls SJ: Sex Differences in Nonculprit Coronary Plaque Micro-structures on Frequency-Domain Optical Coherence Tomography in Acute Coronary Syndromes and Stable Coronary Artery Disease. Circ Cardiovasc Imaging, 2016; 9: pii:e004506","DOI":"10.1161\/CIRCIMAGING.116.004506"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Kataoka Y, Puri R, Hammadah M, Duggal B, Uno K, Kapadia SR, Tuzcu EM, Nissen SE, Nicholls SJ: Frequency-domain optical coherence tomographic analysis of plaque microstructures at nonculprit narrowings in patients receiving potent statin therapy. Am J Cardiol, 2014; 114: 549-554","DOI":"10.1016\/j.amjcard.2014.05.035"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Komukai K, Kubo T, Kitabata H, Matsuo Y, Ozaki Y, Takarada S, Okumoto Y, Shiono Y, Orii M, Shimamura K, Ueno S, Yamano T, Tanimoto T, Ino Y, Yamaguchi T, Kumiko H, Tanaka A, Imanishi T, Akagi H, Akasaka T: Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study. J Am Coll Cardiol, 2014; 64: 2207-2217","DOI":"10.1016\/j.jacc.2014.08.045"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Kataoka Y, Hammadah M, Puri R, Duggal B, Uno K, Kapadia SR, Murat Tuzcu E, Nissen SE, Nicholls SJ: Plaque microstructures in patients with coronary artery disease who achieved very low low-density lipoprotein cholesterol levels. Atherosclerosis, 2015; 242: 490-495","DOI":"10.1016\/j.atherosclerosis.2015.08.005"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Kataoka Y, Hammadah M, Puri R, Duggal B, Uno K, Kapadia SR, Tuzcu EM, Nissen SE, Nicholls SJ: Plaque vulnerability at non-culprit lesions in obese patients with coronary artery disease: Frequency-domain optical coherence tomography analysis. Eur J Prev Cardiol, 2015; 22: 1331-1339","DOI":"10.1177\/2047487315598711"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Hattori K, Ozaki Y, Ismail TF, Okumura M, Naruse H, Kan S, Ishikawa M, Kawai T, Ohta M, Kawai H, Hashimoto T, Takagi Y, Ishii J, Serruys PW, Narula J: Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS. JACC Cardiovasc Imaging, 2012; 5: 169-177","DOI":"10.1016\/j.jcmg.2011.11.012"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Takarada S, Imanishi T, Kubo T, Tanimoto T, Kitabata H, Nakamura N, Tanaka A, Mizukoshi M, Akasaka T: Effect of statin therapy on coronary fibrous-cap thickness in patients with acute coronary syndrome: assessment by optical coherence tomography study. Atherosclerosis, 2009; 202: 491-497","DOI":"10.1016\/j.atherosclerosis.2008.05.014"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Hou J, Xing L, Jia H, Vergallo R, Soeda T, Minami Y, Hu S, Yang S, Zhang S, Lee H, Yu B, Jang IK: Comparison of Intensive Versus Moderate Lipid-Lowering Therapy on Fibrous Cap and Atheroma Volume of Coronary Lipid-Rich Plaque Using Serial Optical Coherence Tomography and Intravascular Ultrasound Imaging. Am J Cardiol, 2016; 117: 800-806","DOI":"10.1016\/j.amjcard.2015.11.062"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Katsiki N, Theocharidou E, Karagiannis A, Athyros VG, Mikhailidis DP: Ezetimibe therapy for dyslipidemia: an update. Curr Pharm Des, 2013; 19: 3107-3114","DOI":"10.2174\/13816128113199990314"},{"key":"37","doi-asserted-by":"crossref","unstructured":"38) Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators: Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med, 2015; 372: 2387-2397","DOI":"10.1056\/NEJMoa1410489"},{"key":"38","doi-asserted-by":"crossref","unstructured":"39) Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group: High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA, 2005; 294: 2437-2445","DOI":"10.1001\/jama.294.19.2437"},{"key":"39","doi-asserted-by":"crossref","unstructured":"40) LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005; 352: 1425-1435","DOI":"10.1056\/NEJMoa050461"},{"key":"40","doi-asserted-by":"crossref","unstructured":"41) Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med, 1977; 62: 707-714","DOI":"10.1016\/0002-9343(77)90874-9"},{"key":"41","doi-asserted-by":"crossref","unstructured":"42) Rhoads GG, Gulbrandsen CL, Kagan A: Serum lipoproteins and coronary heart disease in a population study of Hawaii Japanese men. N Engl J Med, 1976; 294: 293-298","DOI":"10.1056\/NEJM197602052940601"},{"key":"42","doi-asserted-by":"crossref","unstructured":"43) Jacobs DR Jr, Mebane IL, Bangdlwala SI, Criqui MH, Tyroler HA: High-density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: the follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol, 1990; 131: 32-47","DOI":"10.1093\/oxfordjournals.aje.a115483"},{"key":"43","doi-asserted-by":"crossref","unstructured":"44) Olsson AG, Schwartz GG, Szarek M, Sasiela WJ, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A: High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J, 2005; 26: 890-896","DOI":"10.1093\/eurheartj\/ehi186"},{"key":"44","doi-asserted-by":"crossref","unstructured":"45) Ray KK, Cannon CP, Cairns R, Morrow DA, Ridker PM, Braunwald E: Prognostic utility of apoB\/AI, total cholesterol\/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE ITTIMI 22. Arterioscler Thromb Vasc Biol, 2009; 29: 424-430","DOI":"10.1161\/ATVBAHA.108.181735"},{"key":"45","doi-asserted-by":"crossref","unstructured":"46) Ridker PM, Genest J, Boekholdt SM, Libby P, Gotto AM, Nordestgaard BG, Mora S, MacFadyen JG, Glynn RJ, Kastelein JJ; JUPITER Trial Study: HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet, 2010; 376: 333-339","DOI":"10.1016\/S0140-6736(10)60713-1"},{"key":"46","doi-asserted-by":"crossref","unstructured":"47) Gotto AM, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langend\u00f6rfer A, Beere PA, Watson DJ, Downs JR, de Cani JS: Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force\/TexAs Coronary Atherosclerosis Prevention Study (AFCAPS\/ TexCAPS). Circulation, 2000; 101: 477-484","DOI":"10.1161\/01.CIR.101.5.477"},{"key":"47","doi-asserted-by":"crossref","unstructured":"48) Sacks FM, Moye LA, Davis BR, Cole TG, Rouleau JL, Nash DT, Pfeffer MA, Braunwald E: Relationship between plasma LDL concentration during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial. Circulation, 1998; 97: 1446-1452","DOI":"10.1161\/01.CIR.97.15.1446"},{"key":"48","doi-asserted-by":"crossref","unstructured":"49) Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, Welch KM, Amarenco P, Demicco DA, Tonkin AM, Sullivan DR, Kirby A, Colhoun HM, Hitman GA, Betteridge DJ, Durrington PN, Clearfield MB, Downs JR, Gotto AM Jr, Ridker PM, Kastelein JJ: Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation, 2013; 128: 1504-1512","DOI":"10.1161\/CIRCULATIONAHA.113.002670"},{"key":"49","doi-asserted-by":"crossref","unstructured":"50) Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA, 2007; 298: 299-308","DOI":"10.1001\/jama.298.3.299"},{"key":"50","doi-asserted-by":"crossref","unstructured":"51) Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA, 2007; 298: 309-316","DOI":"10.1001\/jama.298.3.309"},{"key":"51","doi-asserted-by":"crossref","unstructured":"52) Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG: Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA, 2008; 300: 2142-2152","DOI":"10.1001\/jama.2008.621"},{"key":"52","doi-asserted-by":"crossref","unstructured":"53) Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J: Major lipids, apolipoproteins, and risk of vascular disease. JAMA, 2009; 302: 1993-2000","DOI":"10.1001\/jama.2009.1619"},{"key":"53","doi-asserted-by":"crossref","unstructured":"54) Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E; PROVE IT-TIMI 22 Investigators: Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE ITTIMI 22 trial. J Am Coll Cardiol, 2008; 51: 724-730","DOI":"10.1016\/j.jacc.2007.10.038"},{"key":"54","doi-asserted-by":"crossref","unstructured":"55) Faergeman O, Holme I, Fayyad R, Bhatia S, Grundy SM, Kastelein JJ, LaRosa JC, Larsen ML, Lindahl C, Olsson AG, Tikkanen MJ, Waters DD, Pedersen TR; Steering Committees of IDEAL and TNT Trials: Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. Am J Cardiol, 2009; 104: 459-463","DOI":"10.1016\/j.amjcard.2009.04.008"},{"key":"55","doi-asserted-by":"crossref","unstructured":"56) Rader DJ, Hovingh GK: HDL and cardiovascular disease. Lancet, 2014; 384: 618-625","DOI":"10.1016\/S0140-6736(14)61217-4"},{"key":"56","doi-asserted-by":"crossref","unstructured":"57) Fisher EA, Feig JE, Hewing B, Hazen SL, Smith JD: High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol, 2012; 32: 2813-2820","DOI":"10.1161\/ATVBAHA.112.300133"},{"key":"57","doi-asserted-by":"crossref","unstructured":"58) Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA: High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation, 1989; 79: 8-15","DOI":"10.1161\/01.CIR.79.1.8"},{"key":"58","doi-asserted-by":"crossref","unstructured":"59) Rohatgi A, Khera A, Berry JD, Givens EG, Ayers CR, Wedin KE, Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, Shaul PW: HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med, 2014; 371: 2383-2393","DOI":"10.1056\/NEJMoa1409065"},{"key":"59","doi-asserted-by":"crossref","unstructured":"60) Ozaki Y, Tanaka A, Komukai K, Ishibashi K, Tanimoto T, Kitabata H, Ino Y, Kubo T, Imanishi T, Akasaka T: High-density lipoprotein cholesterol level is associated with fibrous cap thickness in acute coronary syndrome. Circ J, 2013; 77: 2982-2989","DOI":"10.1253\/circj.CJ-13-0512"},{"key":"60","doi-asserted-by":"crossref","unstructured":"61) Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nu\u00f1ez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E: NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature, 2010; 464: 1357-1361","DOI":"10.1038\/nature08938"},{"key":"61","doi-asserted-by":"crossref","unstructured":"62) Rajam\u00e4ki K, Lappalainen J, O\u00f6rni K, V\u00e4lim\u00e4ki E, Matikainen S, Kovanen PT, Eklund KK: Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One, 2010; 5: e11765","DOI":"10.1371\/journal.pone.0011765"},{"key":"62","doi-asserted-by":"crossref","unstructured":"63) Kellner-Weibel G, Jerome WG, Small DM, Warner GJ, Stoltenborg JK, Kearney MA, Corjay MH, Phillips MC, Rothblat GH: Effects of intracellular free cholesterol accumulation on macrophage viability: a model for foam cell death. Arterioscler Thromb Vasc Biol, 1998; 18: 423-431","DOI":"10.1161\/01.ATV.18.3.423"},{"key":"63","doi-asserted-by":"crossref","unstructured":"64) Geng YJ, Phillips JE, Mason RP, Casscells SW: Cholesterol crystallization and macrophage apoptosis: implication for atherosclerotic plaque instability and rupture. Biochem Pharmacol, 2003; 66: 1485-1492","DOI":"10.1016\/S0006-2952(03)00502-1"},{"key":"64","doi-asserted-by":"crossref","unstructured":"65) Kataoka Y, Puri R, Hammadah M, Duggal B, Uno K, Kapadia SR, Tuzcu EM, Nissen SE, Nicholls SJ: Cholesterol crystals associate with coronary plaque vulnerability in vivo. J Am Coll Cardiol, 2015; 65: 630-632","DOI":"10.1016\/j.jacc.2014.11.039"},{"key":"65","unstructured":"66) Nishimura S, Ehara S, Hasegawa T, Matsumoto K, Yoshikawa J, Shimada K: Cholesterol crystal as a new feature of coronary vulnerable plaques: An optical coherence tomography study. J Cardiol, 2016 May 4. pii: S0914-5087(16)30049-1"},{"key":"66","doi-asserted-by":"crossref","unstructured":"67) Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med, 2007; 357: 2109-2122","DOI":"10.1056\/NEJMoa0706628"},{"key":"67","doi-asserted-by":"crossref","unstructured":"68) Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, Ruzyllo W, Bachinsky WB, Lasala GP, Tuzcu EM; ILLUSTRATE Investigators: Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med, 2007; 356: 1304-1316","DOI":"10.1056\/NEJMoa070635"},{"key":"68","doi-asserted-by":"crossref","unstructured":"69) Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, Hu B, McErlean E, Nissen SE: Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA, 2011; 306: 2099-2109","DOI":"10.1001\/jama.2011.1649"},{"key":"69","doi-asserted-by":"crossref","unstructured":"70) Bailey D, Jahagirdar R, Gordon A, Hafiane A, Campbell S, Chatur S, Wagner GS, Hansen HC, Chiacchia FS, Johansson J, Krimbou L, Wong NC, Genest J: RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol, 2010; 55: 2580-2589.","DOI":"10.1016\/j.jacc.2010.02.035"},{"key":"70","doi-asserted-by":"crossref","unstructured":"71) Nicholls SJ, Puri R, Wolski K, Ballantyne CM, Barter PJ, Brewer HB, Kastelein JJ, Hu B, Uno K, Kataoka Y, Herrman JP, Merkely B, Borgman M, Nissen SE: Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial. Am J Cardiovasc Drugs, 2016; 16: 55-65.","DOI":"10.1007\/s40256-015-0146-z"},{"key":"71","doi-asserted-by":"crossref","unstructured":"72) Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S; American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism.; Council on Arteriosclerosis, Thrombosis and Vascular Biology.; Council on Cardiovascular Nursing.; Council on the Kidney in Cardiovascular Disease: Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation, 2011; 123: 2292-2333","DOI":"10.1161\/CIR.0b013e3182160726"},{"key":"72","doi-asserted-by":"crossref","unstructured":"73) Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Bor\u00e9n J, Catapano AL, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokg\u00f6zoglu L, Tybj\u00e6rg-Hansen A, Watts GF; European Atherosclerosis Society Consensus Panel: Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J, 2011; 32: 1345-1361","DOI":"10.1093\/eurheartj\/ehr112"},{"key":"73","unstructured":"74) Kataoka Y, Andrews J, Uno K, Puri R, Hammadah M, Duggal B, Kapadia SR, Tuzcu EM, Nissen SE, Nicholls SJ: Triglyceride\/high-density lipoprotein cholesterol ratio associates with plaque instability in diabetic patients receiving a statin: frequency domain optical coherence tomography analysis. Eur Heart J, 2016; 37 supple1: 735"},{"key":"74","doi-asserted-by":"crossref","unstructured":"75) ACCORD Study Group. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP: Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med, 2010; 362: 1563-1574","DOI":"10.1056\/NEJMoa1001282"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/24\/4\/24_RV16009\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T21:12:32Z","timestamp":1568841152000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/24\/4\/24_RV16009\/_article"}},"subtitle":["Insights from Optical Coherence Tomography Imaging"],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":74,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.rv16009","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017]]}}}